2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f [g] h i j k l m n o p q r s t u v w x y z

Abstract Number: 2818

Galectin-3 As a Marker of Subclinical Atherosclerosis, Arterial Stiffness and Myocardial Performance in Patients with Rheumatoid Arthritis
Abstract Number: 2040

Galectin-3 Is a Regulator of 4-1BB/CD137 Activity and Associates with Outcome in Rheumatoid Arthritis.
Abstract Number: 270

Gaps in Knowledge about the Ontario Trillium Drug Program
Abstract Number: 2858

Gaps in Patient Safety Performance before Treatment with Biologic Disease-Modifying Antirheumatic Drugs or Tofacitinib in a Large Academic Healthcare System
Abstract Number: 790

Gastrointestinal Symptom Burden and Quality of Life in Systemic Sclerosis: Understanding the Role of Diet
Abstract Number: 133

GBR830, a True OX40 Antagonist Antibody with Potent Suppressive Effects on T Cell-Mediated Pathological Responses
Abstract Number: 276

Gender Differences in TNFi Treatment Adherence and Response in As Patients: A Prospective Longitudinal Cohort Study
Abstract Number: 1603

Gender-Specific Differences in Chinese Patients with Ankylosing Spondylitis
Abstract Number: 1969

GENE Enhancers Associated with an Increase Risk of Developing JIA Fail to DOWN Regulate RUNX1 after CELL Stimulation
Abstract Number: 1958

Gene Expression Pathways across Multiple Tissues in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Reveal Core Pathways of Disease Pathology
Abstract Number: 1109

Gene Expressions of TMEM176A and TMEM176B Were Prominent at the Stage of Subclinical Pulmonary Vascular Disease in Systemic Sclerosis
Abstract Number: 873

General Safety of Febuxostat and Allopurinol in a Cardiovascular Outcomes Study in Patients with Gout
Abstract Number: 2007

Generation of Human Induced Pluripotent Stem Cell Lines from Patients with Hand Osteoarthritis
Abstract Number: 51

Genetic Ablation of Inducible Nitric Oxide Synthase in TNF Transgenic Mice with Inflammatory-Erosive Arthritis Prevents Lymph Node Expansion and Decreases Synovial Infiltrates
Abstract Number: 1827

Genetic Ablation of Phd Finger Protein 19 Gene Promotes Autoimmune Arthritis in Mice
Abstract Number: 2105

Genetic Analysis of a Drosophila Systemic Lupus Erythematosus Model Reveals Lupus Susceptibility Genes
Abstract Number: 565

Genetic Polymorphism in Dihydrofolate Reductase Impacts Methotrexate Polyglutamation in Adult Rheumatoid Arthritis
Abstract Number: 836

Genetic Risk Score Prediction in Ankylosing Spondylitis
Abstract Number: 1119

Genetic Signatures from RNA Sequencing of Pediatric Localized Scleroderma (LS) Skin
Abstract Number: 2248

Genetic Variants Identify Interleukin 37 As an Important Anti-Inflammatory Cytokine in Gout in Humans
Abstract Number: 1978

Genome Wide Association Studies in SLE Predict E-Genes and Gene Expression Patterns That Inform Ancestral-Specific Molecular Pathways and Targeted Therapies
Abstract Number: 2061

Genome-Wide DNA Methylation Analysis in Ankylosing Spondylitis
Abstract Number: 1135

Genome-Wide Meta-Analysis Identified Two Novel Variants Associated with Hallux Valgus
Abstract Number: 2748

Giant Cell Arteritis in Treatment with Tocilizumab. Evolution of Vascular FDG Uptake on PET/CT
Abstract Number: 2744

Giant-Cell Arteritis: Is Glucocorticoid-Sparing Treatment Still Relevant? a Retrospective Study
Abstract Number: 1714

Global Consensus Building and Prioritization of Major Challenges in Lupus Diagnosis, Care, Treatment and Research
Abstract Number: 2053

Global Mirna Expression and Transcriptomic Profiling of Monocytes from RA Patients
Abstract Number: 2104

Glomerular and Tubular Transcriptional Profiles Reveal Gene Clusters Specific for Different Stages of Glomerulonephritis in NZM2328 Mice
Abstract Number: 2093

Glucocorticoid-Induced Leucine Zipper (GILZ) Deficiency Worsens Autoimmunity in the Lyn-Deficient Murine Model of Lupus By Disinhibiting the Type I Interferon (IFN) Pathway
Abstract Number: 2092

Glucocorticoid-Induced Leucine Zipper (GILZ) Is a Novel Checkpoint Regulator of Type I Interferon (IFN) Production in SLE
Abstract Number: 2679

Glucocorticoids Withdrawal in Systemic Lupus Erythematosus: Are Remission and Low Disease Activity Reliable Starting Points for Stopping Therapy? a Real-Life Experience
Abstract Number: 100

Glycosphingolipids and Proteins in Urine Exosomes: Potential Biomarkers of Lupus Nephritis
Abstract Number: 1925

Goal Concordance in Rheumatoid Arthritis: Beyond Pain Reduction, Is There Agreement?
Abstract Number: 2595

Golimumab Improves Socio- and Health Economic Parameters in Patients with RA, Psa and As: Real World-Data from a Non-Interventional Clinical Study in Germany
Abstract Number: 1386

Golimumab Improves Work Productivity and Activity As Well As Quality of Life in Patients with Rheumatoid Arthritis (RA), Psoriasis Arthritis (PsA) and Axial Spondyloarthritis (axSpA): Interim Results from a Non-Interventional Study in Austria (Go Active)
Abstract Number: 1147

Golimumab Improves Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): 1-Year Results from a Non- Interventional Trial in Germany
Abstract Number: 2416

Good Pregnancy and Neonatal Outcomes in Lupus Nephritis Patients with Complete Remission
Abstract Number: 1126

Gout and Chronic Pain in Older Adults: A Medicare Claims Study
Abstract Number: 2226

Gout and the Risk of Incident Dementia in the Elderly: A Medicare Claims Study
Abstract Number: 1298

Gout and the Risk of Parkinson’s Disease in Older Adults: A Study of U.S. Medicare Data
Abstract Number: 2220

Gout, Flares and Allopurinol Use: A Population Based Study
Abstract Number: 944

Gout: A Potential Risk Factor for Uveitis in the Older Adults?
Abstract Number: 2289

Granulomatous Myositis: Heterogeneity and Response to Treatment
Abstract Number: 1818

Greater BMD Gains with Denosumab Vs Risedronate in Glucocorticoid-Treated Subjects: Results from the Final 24-Month Analysis of a Randomized, Double-Blind, Double-Dummy Study
Abstract Number: 2518

GS-9876, a Novel, Highly Selective, SYK Inhibitor in Patients with Active Rheumatoid Arthritis: Safety, Tolerability and Efficacy Results of a Phase 2 Study
Abstract Number: 990

Guanylate Binding Protein 5 (GBP5) Inhibits Rheumatoid Arthritis Synovial Fibroblast Mediated Inflammation and Tissue Destruction
Abstract Number: 1251

Guideline Adherence for Perioperative Use of Immunosuppressive Medications in Patients with Rheumatologic Disease
Abstract Number: 1828

Gut-Joint T Cell Trafficking in a Model of Bacteria-Driven Murine IBD-Spa

Jump to: View All • a b c d e f [g] h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].